ADAP vs. RNAC, ANNX, CGC, TSVT, DBVT, PVLA, CADL, CRDF, INZY, and IMMP
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Cartesian Therapeutics (RNAC), Annexon (ANNX), Canopy Growth (CGC), 2seventy bio (TSVT), DBV Technologies (DBVT), Palvella Therapeutics (PVLA), Candel Therapeutics (CADL), Cardiff Oncology (CRDF), Inozyme Pharma (INZY), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry.
Adaptimmune Therapeutics vs. Its Competitors
Cartesian Therapeutics (NASDAQ:RNAC) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.
In the previous week, Cartesian Therapeutics had 1 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 1 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.24 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media.
Adaptimmune Therapeutics received 290 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 63.39% of users gave Adaptimmune Therapeutics an outperform vote.
Cartesian Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500.
Adaptimmune Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Adaptimmune Therapeutics has a net margin of -38.91% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Adaptimmune Therapeutics' return on equity.
Cartesian Therapeutics presently has a consensus price target of $41.25, indicating a potential upside of 319.63%. Adaptimmune Therapeutics has a consensus price target of $1.52, indicating a potential upside of 526.38%. Given Adaptimmune Therapeutics' higher probable upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than Cartesian Therapeutics.
Summary
Cartesian Therapeutics beats Adaptimmune Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ADAP) was last updated on 6/24/2025 by MarketBeat.com Staff
Buy ADAP Stock Free ADAP Stock Alerts